Spots Global Cancer Trial Database for rifampicin
Every month we try and update this database with for rifampicin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib | NCT04959266 | Advanced Solid ... | Adavosertib Itraconazole Rifampicin Omeprazole | 18 Years - 130 Years | AstraZeneca | |
| A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor | NCT05372367 | Solid Tumors | BI 907828 Rifampicin Itraconazole | 18 Years - 70 Years | Boehringer Ingelheim | |
| A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor | NCT05372367 | Solid Tumors | BI 907828 Rifampicin Itraconazole | 18 Years - 70 Years | Boehringer Ingelheim | |
| A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential | NCT02706535 | Drug Interactio... Neoplasms | GSK525762 Besyl... Itraconazole 20... Rifampicin 300 ... | 18 Years - 70 Years | GlaxoSmithKline | |
| Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours | NCT01929603 | Solid Tumours | Pharmacokinetic... Rifampicin Olaparib tablet... | 18 Years - 99 Years | AstraZeneca | |
| To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors | NCT03002493 | Tumor | Eribulin mesyla... Eribulin mesyla... Rifampicin | 18 Years - | Eisai Inc. | |
| A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential | NCT02706535 | Drug Interactio... Neoplasms | GSK525762 Besyl... Itraconazole 20... Rifampicin 300 ... | 18 Years - 70 Years | GlaxoSmithKline | |
| To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers | NCT02046850 | Solid Tumours | selumetinib rifampicin selumetinib rifampicin | 18 Years - 45 Years | AstraZeneca | |
| To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers | NCT02046850 | Solid Tumours | selumetinib rifampicin selumetinib rifampicin | 18 Years - 45 Years | AstraZeneca | |
| Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC | NCT02197247 | Non Small Cell ... | Pharmacokinetic... Rifampicin AZD9291 tablet ... Pharmacokinetic... Pharmacokinetic... | 18 Years - 130 Years | AstraZeneca | |
| Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours | NCT00750841 | Solid Tumors | cediranib | 18 Years - 130 Years | AstraZeneca | |
| To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors | NCT03002493 | Tumor | Eribulin mesyla... Eribulin mesyla... Rifampicin | 18 Years - | Eisai Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
